Japan’s pharma markets overview
Japan’s pharmaceutical market is the third largest globally:
- USA: US$ 425 billion (2020)
- Europa: US$ 200 billion (2020)
- Japan: US$ 150 billion (2020)
Japan’s pharma industry includes many different segments from
- traditional pharma companies (including the 15 largest are listed below),
- new entrants (eg brewery companies, electrical conglomerates, chemical conglomerates, rubber companies…. entering the life science sector)
- pharma manufacturing, contract cell manufacturers (eg FujiFilm)
- ventures (eg cell therapy, regenerative medicine sectors)
- medical equipment (eg Olympus)
- and other sectors
For our business development and M&A work we are continuously developing a large proprietary data base of Japan’s pharmaceutical industry, medical equipment, and related industries, research institutions, ventures, venture funds, and industry associations.
Our platform includes on the order of
- 110 Japanese pharmaceutical companies (far beyond the top 15 listed below, and including a long tail of small and mid-sized pharma companies and ventures),
- 230 Japanese companies in the regenerative medicine, cell therapy sector
- data base of pharma organizations, research centers, research parks, venture funds, research organizations and more
Japan’s top 15 pharma groups
Ranking depends on criteria and varies year by year:
- Chugai (Hoffmann-La Roche holds 61.16% of shares excluding treasury stock, 59.89% of outstanding shares) sales US$ 5.2 billion (2022)
- Takeda US$ 5 billion
- Eisai US$ 4 billion
- Astellas US$ 3.8 billion
- Otsuka Holdings US$ 3.6 billion
- Daiichi Sankyo US$ 3.2 billion
- Mitsubishi Tanabe Pharma (absorbed by Mitsubishi Chemical) US$ 2.7 billion
- Sawai Pharmaceutical US$ 2 billion
- Kyowa Hakko Kirin US$ 1.8 billion
- Shionogi US$ 1.6 billion
- Santen Pharma US$ 1.5 billion
- Ono Pharma US$ 1.3 billion
- Nippon Shinyaku US$ 1.2 billion
- Sumitomo Pharma (was Sumitomo Dainippon Pharma) US$ 1.1 billion
- Mochida Pharma US$ 1 billion
(c) 2024 Eurotechnology Japan KK All rights reserved.